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Abstract
Human APOBEC3 cytidine deaminases are intrinsic resistance factors to HIV-1. However,
HIV-1 encodes a viral infectivity factor (Vif) that degrades APOBEC3 proteins. In vitro APO-
BEC3F (A3F) anti-HIV-1 activity is weaker than A3G but is partially resistant to Vif degrada-
tion unlike A3G. It is unknown whether A3F protein affects HIV-1 disease in vivo. To assess
the effect of A3F gene on host susceptibility to HIV- acquisition and disease progression,
we performed a genetic association study in six well-characterized HIV-1 natural cohorts. A
common six-Single Nucleotide Polymorphism (SNP) haplotype of A3F tagged by a codon-
changing variant (p. I231V, with allele (V) frequency of 48% in European Americans) was
associated with significantly lower set-point viral load and slower rate of progression to
AIDS (Relative Hazards (RH) = 0.71, 95% CI: 0.56, 0.91) and delayed development of
pneumocystis pneumonia (PCP) (RH = 0.53, 95% CI: 0.37–0.76). A validation study in the
International Collaboration for the Genomics of HIV (ICGH) showed a consistent associa-
tion with lower set-point viral load. An in vitro assay revealed that the A3F I231V variant may
influence Vif mediated A3F degradation. Our results provide genetic epidemiological evi-
dence that A3F modulates HIV-1/AIDS disease progression.
Author Summary
Cytidine deaminases of the human APOBEC3 (A3) gene family serve as intrinsic resis-
tance factors to HIV-1 and other retroviruses. HIV-1 encodes the viral infectivity factor
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(Vif) protein that degrades APOBEC3 proteins via the ubiquitination-proteosomal path-
way. APOBEC3F (A3F), unlike APOBEC3G (A3G), is partially resistant to Vif-mediated
degradation. The antiviral activity of the A3 family has largely been demonstrated in in
vitro experiments, and there is mounting evidence that A3G genetic variants influence
HIV disease progression. It is not resolved if A3F protein affects HIV disease in vivo. To
assess the in vivo effect of A3F, we performed a genetic association study of genetic vari-
ants in A3F for their influence on HIV- acquisition and HIV disease progression. A com-
mon A3F haplotype was associated with a 30% reduced rate of AIDS disease progression,
lower set-point viral load and delayed development of pneumocystis pneumonia (PCP) in
European Americans. This study provides the first epidemiological evidence that A3F
might modify HIV-1/AIDS pathogenesis.
Introduction
The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3, A3) pro-
teins are a family of cellular cytidine deaminases that defend against a diverse set of retrovi-
ruses, endogenous retroelements and DNA viruses, including human immunodeficiency virus
type I (HIV-1) [1–5]. Humans A3 proteins are encoded by seven A3 genes (A3A, A3B, A3C,
A3D, A3F, A3G, and A3H) tandemly arrayed on chromosome 22. In in vitro experimental sys-
tems, several members of the human APOBEC3 family are capable of inhibiting HIV-1 replica-
tion to some degree (A3G, A3F, A3D and some A3H haplotypes), with A3G and A3F showing
evidence of strong inhibitory activity. A3G protein catalyzes deamination of cytosine bases on
the DNA minus strand during reverse transcription, inducing guanosine (G)-to-adenosine (A)
hypermutation in the HIV-1 provirus [2,6–8]. A3G causes GG-to-AG transitions, while APO-
BEC3F causes GA-to-AA nucleotide changes. However, HIV-1 encodes an accessory protein,
viral infectivity factor (Vif), to counteract APOBEC3 proteins by mediating the proteasomal
degradation of A3 proteins [9–13]. It is unknown whether the anti-HIV-1 activity of A3 pro-
teins is completely neutralized by Vif or if A3 still exerts meaningful antiviral effect in vivo.
While G to A hypermutation of the HIV genome is deleterious to the virus [10], [16–18], a
recent in vitro study showed sub-lethal levels of A3G induced G to A mutations may contribute
to viral diversity, which consequently may contribute to immune escape and drug resistance
[14]. How A3 proteins’ opposing antiviral and viral mutation properties contribute to HIV-1
pathogenesis in vivo is a critical question.
The antiviral strength of A3F is unresolved by in vitro experiments as some reported that
A3F activity is as strong as A3G [7,15–17] while others indicated that it is weaker [18–21], pos-
sibly due to varied experimental settings. A3F is highly expressed in CD4+ T-cells, the cells
infected by HIV-1 [22,23]. Unlike A3G, A3F is partially resistant to Vif-mediated degradation
[15]. A3F also has a favored deamination sequence target that differs from A3G (50-TC for A3F
and 50-CC for A3G) [24]. Patterns of HIV DNA hypermutation observed in HIV-1 infected
individuals are consistent with the notion that both A3G and A3F might be acting on HIV-1 in
vivo [25].
Testing the in vivo role of intrinsic host restriction factors such as A3 proteins are challeng-
ing due to a lack of a good animal model [26,27]. The genetic associations between natural
polymorphisms in A3 genes and resistance to infection to HIV-1or restriction to HIV-1 disease
progression would provide critical evidence supporting an in vivo role for A3 proteins in
restricting HIV. Genetic variation in A3G and A3H have been shown to associate with HIV-1
disease progression [28–30], supporting the in vivo activity of A3G and A3H’s. However, it
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remains unknown whether A3F confers any appreciable effect on HIV acquisition or HIV
pathogenesis. We investigated the association of variants in the A3F gene with susceptibility to
HIV-1 acquisition, HIV-1 viral load, and progression to AIDS in six clinically well-character-
ized, natural history HIV cohorts.
Results
Linkage disequilibrium, haplotype structure and characteristics of A3F
variants
A3F is about 17 kb in length, containing 7 exons. Six potentially functional SNPs, including the
missense SNP rs2076101 ATC>GTC, coding p.I231V, were genotyped in the AIDS cohorts
(Fig 1 and Table 1). The allele rs2076101G (231V) had a frequency of 48% in European
Fig 1. SNPs analyzed in the A3F gene. (A) Gene structure and SNP locations. The colored blocks indicate exons, empty blocks, untranslated regions
(UTR), horizontal arrows, the direction of transcription and vertical arrows, the positions of SNPs. (B) Linkage disequilibriummatrix of SNPs in the A3F gene
region in European Americans, as illustrated by Haploview [74]. Red block indicates D’ = 1.0, and the number in the blocks indicates the value of D’. The
linkage disequilibrium block depicted by black triangle was based on the 95% Confidence interval criteria. (C) Haplotypes in the A3F gene region in European
Americans.
doi:10.1371/journal.pgen.1005921.g001
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Americans (EA) and 76% in African Americans (AA) in our cohorts. Genotype distributions
of the 6 SNPs conformed to Hardy-Weinberg equilibrium expectations (P> 0.05) in European
Americans and African Americans. The 6 SNPs were in near-absolute linkage disequilibrium
(LD) and highly correlated (D’ = 1 and r2>0.95, respectively) in EA. SNP rs2076101A/G (p.
I231V) tags the most frequent A3F haplotype comprising the variant alleles of all 6 SNPs (Fig
1); we therefore used rs2076101A/G (p.I231V) to represent the A3F haplotype in the associa-
tion analyses.
Based on HapMap LD map covering the APOBEC3 gene family region (S1 Fig), A3F, 3G,
3H each gene forms a distinct haplotype block but are not in strong LD with each other, as
reported previously [29].
The possible functional consequence of the six SNPs, as evaluated by the Variant Effect Pre-
dictor (VEP) function from Ensembl (www.ensembl.org/), is listed in Table 1. The missense
SNP rs2076101 (p.I231V) results in a change from isoleucine to valine, has a Polyphen score of
0.90, reflecting a non-conservative change with possible deleterious consequence. SNP
rs5750728 is located in the intron of A3F encoding the major transcript; however, the shorter
transcript encoding 101 amino acids (NM_0010066666) would contain p.V78A, a benign
change. Whether this isoform is functional in vivo is still unknown. SNP rs5750727 in intron 1
is located within an experimentally identified regulatory feature in CD4+ T-cells
(ENSR00001532770, based on Ensembl database).
Impact of A3F 231V haplotype on HIV-1 progression
To assess the impact of the A3F 231V haplotype on disease progression from the estimated
date of seroconversion to clinical AIDS, we performed time-to-event analysis for 707 European
American seroconverters. The seroconversion date was estimated as the midpoint between the
last seronegative and the first seropositive HIV-1 antibody test date (mean seroconversion
interval 0.89 years, range 0.06–3.0 years). In the Kaplan-Meier survival curve analysis, p. 231V
was associated with delayed progression to clinical AIDS (Fig 2A) (P = 0.02, in both log-rank
andWilcoxon test) in the dominant genetic model. To account for covariates (age, sex, and
cohort) and genetic confounders (CCR5 andHLA variants), we employed adjusted Cox pro-
portional hazards regression models to evaluate progression rates to clinical AIDS in 707 Euro-
pean American seroconverters. After stratifying by age group, sex and cohort, carriers of one
or two copies of p. 231V showed significantly delayed progression to clinical AIDS (dominant
genetic model, RH = 0.68, 95% CI, 0.54–0.87, P = 0.002); In the model adjusted for the known
genetic factors ofHLA alleles (HLA-C, B27, B57, B35Px,HLA class I homozygosity, and CCR5
(p1 and Δ32)[31,32], the association remained significant (RH = 0.71, 95% CI, 0.56–0.91,
Table 1. Characteristics of A3F genetic variants.
SNP rs# Position on Chr. 22 Location codon change Allele change Predicted SNP functiona Polyphenb
rs5757432 37758865 Intergenic C/T miRNA
rs5750727 37767356 Intron C/G TFBS
rs5750728 37770095 Intron or alternative exon V78A C/T TFBS Splicing(ESE) benign
rs2014881 37775326 Intron A/G
rs2076101 37775500 exon I231V A/G Splicing(ESE), nsSNP possibly damaging
rs5750735 37779601 3'UTR C/T miRNA
aPredicated by SNPinfo web server [http://snpinfo.niehs.nih.gov]); TFBS, transcription factor-binding site; miRNA, MicroRNA-binding sites; nsSNP, non-
synonymous SNP; ESE, exonic splicing enhancer.
bPredicated by Variant Effect Predictor from Ensembl (www.ensembl.org/)
doi:10.1371/journal.pgen.1005921.t001
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Padj. = 0.007, Table 2). Further adjustment for potential population stratification using the first
2 eigenvalues led to similar result (RH = 0.71, 95% CI, 0.55–0. 90; Peigen = 0.006). The A3F asso-
ciation was not attenuated (RH = 0.68, 95% CI, 0.51–0. 90) with additional adjustment for the
Fig 2. Genetic effect of A3F 231V haplotype on AIDS progression. Kaplan-Meier survival curves of A3F-231I/V genotype carriers progression to AIDS
since HIV-1 infection in the (A) combined cohorts. (B) MACS cohort. (C) other cohorts. (D). Kaplan-Meier survival curves of A3F-231I/V genotype carriers for
progression to PCP since HIV-1 infection in 703 seroconverter European Americans. RH and adjusted P values were obtained from a Cox proportional
hazards model. P values for survival curves were obtained from a log-rank test.
doi:10.1371/journal.pgen.1005921.g002
Table 2. Impact of A3F 231V haplotype on AIDS progression assessed by Cox proportional hazards regression model.
Population Disease outcome no. total/events Adjustment RH (95% CI) P
European American AIDS 1987 707/318 unadjusted 0.68 (0.54–0.87) 0.002
707/318 adjusteda 0.71 (0.55–0.90) 0.006
PCP 703/134 unadjusted 0.53 (0.37–0.76) 0.0005
Africa American AIDS 1987 281/48 unadjusted 0.39 (0.12–1.31) 0.12
281/48 adjustedb 0.34 (0.10–1.18) 0.09
Dominant genetic model (231V/V or V/I vs. I/I) was tested and was stratiﬁed by sex, age and cohort.
a adjusted for covariates HLA homozygosity, HLA-C, HLA-B*57, HLA-B*35PX, HLA-B*27, CCR5-Δ32, CCR5-59029 and the ﬁrst 2 eigenvalues
b adjusted for covariates HLA homozygosity, HLA-B*57, HLA-B*35PX, HLA-B*27, and CCR5-59029.
doi:10.1371/journal.pgen.1005921.t002
APOBEC3F and HIV-1
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known HIV progression modifiers A3B gene deletion [33] and A3G 199376C [30]. The effect
was not affected by the potential seroconversion estimate errors; RHs were changed from 0.71
to 0.72, 0.72, respectively, when seroconversion intervals were shortened to< 2.0 (n = 649) or
to<1.5 years (n = 585). The additive genetic model also showed significant association
(RH = 0.80, 95% CI, 0.68–0.95, Peigen = 0.009). Bayesian analysis using the Gibbs sampler with
50,000 iterations provided the same results, indicating the p values are robust. Separated analy-
ses conducted in the MACS cohort alone (Fig 2B) or in the other cohorts (Fig 2C) showed sig-
nificant association in the same direction. These results provide evidence that the haplotype
carrying the 6 variant alleles including p. 231V was associated with a 30% reduced rate of AIDS
disease in European Americans. In 281 African Americans seroconverters, p. 231V trended in
the same direction in a Cox model analysis (RH = 0.35, 95% CI, 0.10–1.19, Padj. = 0.09;
RH = 0.30, 95% CI, 0.07–1.37, P = 0.12 with further adjustment of population stratification).
The protective effect of p. 231V for AIDS progression was also observed in a defined disease
category analysis (S2 Fig), which allows the addition of seroprevalent patients who had not
progressed to AIDS for>10 years (time from seroconversion to AIDS) to the slow progressor
category of seroconverters; only seroconverters were included in the fast category (10 years)
to avoid frailty bias. The prevalence of AIDS protective genotypes 231V/V and 231 I/V was ele-
vated in the slow progressors (Odds ratio (OR) = 0.62, P = 0.004, chi2 test, S2 Fig). The results
of both the survival (Fig 2A and Table 2) and defined disease category analyses (S2 Fig) sup-
port a strong dominant 231V association with delayed progression to clinical AIDS outcome.
A3F 231V haplotype association with pneumocystis pneumonia (PCP)
Multiple different AIDS-defining conditions including opportunistic infections and malignan-
cies are AIDS-defining [34]. In an explanatory data analysis, we tested whether the common
AIDS defining condition, pneumocystis pneumonia was influenced by p.231V. In a Kaplan-
Meier survival curve analysis of 703 seroconverters, carriers of 1 or 2 copies of the p. 231V hap-
lotype showed a significantly slower progression to pneumocystis pneumonia, compared with
231I/I carriers (log-rank test, P = 0.003; Wilcoxon test, P = 0.005, Fig 2D). A Cox model analy-
sis also showed an association of p.231V with delayed progression to PCP (dominant model,
RH = 0.53, 95% CI 0.37–0.76, Wald test Pdom = 0.0005, Table 2; additive model, RH = 0.69,
95% CI 0.54–0.89, P = 0.004; both adjusted for age, sex and cohort). A sensitivity test in the
MACS cohort revealed no impact of PCP prophylaxis usage on the association. In a sensitivity
test performed in 410 MACS seroconverters, adjustment of PCP prophylaxis (n = 138) did not
attenuate the association of p.231V with PCP (RH changed from 0.637 to 0.633). These results
demonstrated that p.231V has a protective association with PCP development. In 278 Africa
American seroconverters, a nonsignificant protective trend to PCP was seen for p.231V homo-
zygote carriers (OR = 0.55, 95% CI, 0.28–1.12, P = 0.10; S3 Fig)
A3F 231V haplotype association with HIV-1 viral load
Among 183 MACS seroconverters with available viral load set-point data, individuals carrying
the p.231V (n = 141) had significantly lower mean viral load than those homozygous for the
p.231I (n = 42) (mean 4.46 ± 0.69 versus 4.72 ± 0.46 log10 copies/ml; P = 0.02). The p.231V
carriers were associated with a 0.27 ± 0.65 log10 lower set-point viral load (equivalent of
1.86-fold copies per ml of plasma). For comparison, heterozygousity for CCR5 Δ32 [35], had a
0.23 ± 0.65 lower viral load (P = 0.04) in this dataset, supporting the validity of the analysis.
To replicate the viral load association result, we obtained the association results of the A3F
SNPs with HIV-1 viral load from the International Collaboration for the Genomics of HIV
(ICGH) that combined genome-wide SNP data from 25 cohorts worldwide [36]. We analyzed
APOBEC3F and HIV-1
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13 Europe- or USA-based cohorts in ICGH including 6 cohorts used in this study with viral
load data available. For independent confirmation, we removed 183 MACS seroconverter sub-
jects used in the above viral load analysis from the ICGH. A meta-analysis of 13 cohorts com-
prising 10,395 seropositives showed a consistent association of A3F rs2076101 (231V) with
lower set-point viral load (β = -0.04, 95% CI, -0.07, -0.01, P = 0.01) in EA (Fig 3A). The associa-
tion was mainly driven by the cohorts used in this study (comprising cohorts MACS, MHCS,
DCG, HGDS, SFCCC and ALIVE), and most other European-ancestry cohorts showed nonsig-
nificant trends in the same direction. In African American subjects, a meta-analysis showed no
association with viral load but a significant protective association was seen for the ALIVE
cohort (95% CI of β, -0.32, -0.02, Fig 3B). Together, these results indicate a modest but consis-
tent association between p.231V and lower viral load.
Impact of A3F 231V on HIV-1 acquisition
No differences in the A3F p.231V frequencies were observed between African- or European Ameri-
can HIV-1 seronegative groups and HIV-1-infected group (S1 Table), indicating that the A3F
genetic variation assessed herein has no obvious effect on susceptibility to HIV-1 acquisition.
A3F rs5750728 alters transcriptional factor binding
The intronic SNP rs5750728 is in near absolute LD with 231V and is predicted to have regula-
tory function (Table 1). We used electrophoretic mobility shift assays (EMSA) to determine if
the variant alters transcription factor binding. The rs5750728 T containing oligonucleotide
probe formed a major DNA-protein complex with HeLa cell nuclear extract, which was nearly
absent when using rs5750728 C containing oligonucleotide (Fig 4A, lanes 3 and 4). The DNA-
protein complex was abolished by the addition of excessive unlabeled competitor probes
Fig 3. HIV-1 viral load levels of A3F 231V allele carriers in multiple HIV-1 cohorts. Forest plot of effect estimates of HIV-1 viral load for the A3F
rs2076101 G allele with 95% confidence intervals per study group (box and whiskers) and after meta-analysis (diamond) in the International Collaboration for
the Genomics of HIV (ICGH) consortium [36]. (A) Meta-analyses for European or European-descents (eur). (B) Meta-analyses for African Americans (aam).
A description of the study groups and cohorts used in the meta-analysis is presented in S3 Table.
doi:10.1371/journal.pgen.1005921.g003
APOBEC3F and HIV-1
PLOS Genetics | DOI:10.1371/journal.pgen.1005921 March 4, 2016 7 / 18
(Fig 4A, lanes 5 and 6), but was not affected by non-specific competitor probes (Fig 4A, lanes
7 and 8), demonstrating the binding specificity. These results indicate that the rs5750728 C var-
iant allele caused a loss of binding to certain transcription factors, although the identity of the
transcription factors is not yet known.
Genomatix software SNPInspector predicted that rs5750728 T/C change generates tran-
scription factor binding sites for E2FF (myc activator/cell cycle regulator), KLFS (Krueppel like
transcription factors), and ZKSCAN3 (zinc finger with KRAB and SCAN domains 3), and loss
of WHNF (winged helix binding sites) (Fig 4B). Another SNP rs5750727 C/G causes lost site
for MRF2 (modulator recognition factor 2).
Fig 4. Allelic-specific protein binding of A3F rs5750728T/C. (A) For the EMSA, two A3F DNA fragments
with rs5750728 T or C allele were incubated with HeLa nuclear extract. The specificity of the intense bands
present in the rs5750728 T lane (lane 3) was demonstrated by adding 200-fold excess of unlabeled T oligo
(lane 5) and unrelated TFIID oligos (lane 7) as competitors. (B) Transcription factor binding sites affected by
the rs5750728 T/C change based on SNPInspector. The C allele of rs5750728 generates E2FF, ZKSCAN3
(matching the positive (+) strand of the rs5750728 residing A3F DNA fragment), KLFS and loss of WHNF
(matching the negative—strand) sites. The rs5750728 site is in red and underlined.
doi:10.1371/journal.pgen.1005921.g004
APOBEC3F and HIV-1
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Influence of A3F 231V haplotype on HIV-1 Vif mediated degradation
HIV-1 Vif recruits Cul5-based CRL E3 ligase to target A3F for ubiquitination and degradation
[37]. To determine whether A3F variants could alter A3F sensitivity to Vif mediated degrada-
tion, A3F I231-V5 and A3F V231-V5 expression vectors were co-transfected with several HIV-
1 Vif expression vectors in HEK293T cells. A3F expression was determined by immunoblotting
using anti-V5 antibodies. A3F I231-V5 and A3F V231-V5 were sensitive to strains 89.6, Yu2,
and SG3 HIV-1 Vif mediated degradation but resistant to AE and BC HIV-1 Vif mediated deg-
radation (Fig 5). Nevertheless, A3F V231-V5 was approximately 39% more resistant (based on
normalized intensity) to HIV-1 AE Vif mediated degradation (Fig 5, lane 8) compared to A3F
I231-V5 (Fig 5, lane 2). A3F V231-V5 was 30% more resistant to HIV-1 Yu2 Vif (Fig 5, lane
11) mediated degradation compared to A3F I231-V5 (Fig 5, lane 5). These data suggest that
A3F variations at position 231 may influence the sensitivity of A3F to certain HIV-1 Vif medi-
ated inactivation.
Influence of A3F 231V haplotype on HIV-1 hypermutation
The effect of rs2076101 on the level of HIV hypermutation was tested using paired human
genotypes and viral sequences from 421 patients in the Swiss HIV Cohort Study. Counts of
GA-to-AA hypermutations likely induced by A3F were quantified as in the Hypermut2 tool
[38]. We observed 8.11(out of 144.95 potential A3F specific G->Amutations, 5.5% hypermu-
tation rate), 8.23 (5.6%) and 8.63 (5.3%) A3F specific G->Amutations in three rs2076101
genotype groups, respectively; the log odds ratio of hypermutation was not higher in individu-
als carrying the A3F 231V than those who don’t (coefficient = 0.0047, P = 0.88, S2 Table).
Discussion
In vitro studies have identified A3F as one of the human APOBEC3 proteins with intrinsic
anti-HIV-1 activity, and A3F unlike A3G is partially resistant to degradation by HIV-1 Vif
[7,15–17]. In this population-based genetic study, we assessed the impact of A3F variation on
HIV-1 disease progression in longitudinal HIV-1/AIDS natural disease cohorts. We found that
the haplotype encoding A3F p. 231V and bearing 5 other variant alleles was significantly asso-
ciated with slower progression to AIDS and lower viral load set-point. This protective effect is
most pronounced for PCP, the most common AIDS-defining disease in the era before effective
Fig 5. Influence of HIV-1 Vif on A3F variant protein expression. HEK293T cells in 12-well plate were co-
transfected with 1 μg of Vif expression vector or a control vector, plus 0.3 μg of A3F-231I-V5 expression
vector encoding a V5-tagged A3F231I protein (lanes 1–6), or plus 0.3 μg of A3F231V-V5 expression vector
encoding a V5-tagged A3F-231V protein (lanes 7–12). At 48 h after transfection, cell lysates were harvested
for immunoblot analysis with indicated antibodies.
doi:10.1371/journal.pgen.1005921.g005
APOBEC3F and HIV-1
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antiretroviral therapy was available. Our results provide genetic evidence supporting an active
role of human A3F in modulating HIV-1 disease in vivo. The observed population level associ-
ations point toward the physiological relevance of A3F, which has long been debated [7,15–
21].
A3F suppresses HIV-1 replication through deaminase-induced G-to-A hypermutations in
viral DNA, as well as deamination-independent impairment of viral reverse transcription and
prevention of HIV DNA integration [15–17,39,40]. The mechanism by which the A3F variant
haplotype influences AIDS pathogenesis is not clear. Mechanistically, the expectation would be
that A3F variant protein isoforms have different abilities in inhibiting HIV replication, either
by change of protein function or abundance. The association of p.231V with lower viral load
supports the idea that A3F ancestral protein isoform containing p. 231V is more effective in
restricting HIV replication compared to the derived protein isoforms. In an in vitroHIV-1
infectivity experiment, comparable or slight stronger inhibitory activity against an HIV-1 X4
strain with the wild type Vif was observed for A3F 231V (45% infectivity) compared with A3F
231I (57% infectivity) [21]. It is possible that over time the inhibitory effects of the variant pro-
tein may lead to detectable differences in disease outcomes. In a HIV-1 vif-A3F degradation
assay, we have also observed that A3F I231V can influence A3F sensitivity to certain HIV-1 Vif
proteins. Altered Vif sensitivity of A3F variation may be a contributing factor for the observed
differences in HIV-1 viral loads in our study population. Direct Sanger sequencing of HIV-1
viral RNA in plasma of patients in the Swiss HIV cohort identified very low levels of G to A
hypermutation, which may represent a small subset of the variation present in the integrated
proviral HIV. Although HIV G to A variation mediated by A3F was not associated with the
A3F I231V genotype, deeper sequencing provirus may be needed to accurately access the role
of A3F genetic variants on HIV editing [41,42]. Further studies are also needed to determine if
A3F variants affects A3F protein function in blocking reverse transcription and or HIV
integration.
Pneumocystis pneumonia, or PCP, caused by the fungus Pneumocystis jirovecii, is the most
common opportunistic infection in untreated AIDS patients [43,44]. PCP often occurs in those
with low CD4+ cell counts<200/mm3; in the MACS cohort, 30% of those patients developed
PCP within 3 years after CD4+ cell counts dropping to<200/mm3 [43]. A3F variation impact
on PCP may be related with altered activity of A3F in the pulmonary inflammatory environ-
ment after CD4+ cell decline. The pathogenesis of PCP is marked with the immune-mediated
pulmonary inflammation involving chemokines and cytokines [44]. Inflammatory stimuli
such as lipopolysaccharide and interferon-α potently induce A3G and A3F protein expression
[45]. Research will be needed to determine if A3F protein is activated in lung inflammation
sites, affecting local viral replication and immune response.
Our study is limited in sample size, especially as the individual cohorts represent different
HIV risk factors and transmission routes; and we are underpowered in the African American
group to detect small or modest effect sizes. In African Americans, lack of significant associa-
tion could be due to small sample size and lower PCP rate (11%) compared to European Amer-
icans (19%). It is also possible that other operational SNPs in African Americans may be
tracking or interacting with A3F 231V. Our results require further replication in other well-
powered cohorts with well-defined clinical AIDS outcome data. The strong linkage disequilib-
rium among multiple SNPs within the A3F gene with various potential functional effects
makes it difficult to clearly identify the causal variants responsible for the phenotypic associa-
tions. In addition to the p. 231V site, other variant alleles carrying on the haplotype may also
potentially affect A3F gene regulatory function as suggested by differential DNA-protein bind-
ing conferred by the intronic SNP rs5750728. Although A3F SNPs were not in strong LD with
other A3 genes, the possibility of A3F SNPs tracking other SNPs in the A3 gene family region
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cannot be completely ruled out due to the high homology among the gene family that pose
technical difficulties in gene-specific genotyping, sequencing and assembly [46].
Our results may shed light on the relative contribution of A3 family members to HIV patho-
genesis in vivo, a critical unanswered question. We and others have identified associations of a
number of genetic variants in the A3 family genes with HIV-1 acquisition or disease progres-
sion [28–30,33]. The H186R of A3G was associated with rapid progression to AIDS in African
Americans [30], higher viral load in South African infected women [47] and rapid disease pro-
gression in infected children [48]. The C40693T variant of A3G [28] [33]may be associated
with increased risk to acquisition, whereas Haplotype I of A3Hmay confer resistance to infec-
tion [29]. A3B has been shown to restrict HIV-1 in experiments using 293 cells lines [3,7,49–
51], but not in the more biologically relevant T-cell lines [52,53]. The impact of the A3B gene
deletion on HIV-1 infection and progression is inconsistent, possibly due to differences in study
designs and case-control selection. We previously reported that the homozygous A3B deletion
(D/D) was associated with increased risk to HIV-1 acquisition by comparing HIV-1 exposed but
uninfected individuals to HIV-1 incident seroconverters, and further that seroconverters pro-
gressed more rapidly to clinical outcomes[33]. In support of this, one study found that the D/D
carriers had a six-fold greater likelihood of having lower CD4+ T cell levels [54]. Other studies
found no associations for infection or progression, but these were suffered from frailty bias which
might have inflated type 2 errors. For example, one study used healthy controls and long-term
non-progressors but not fast progressors [55,56], and the other study used a control group of
HIV-1 negative MSMwho were nearly a decade younger than infected cases[57]; given equal
exposure time, many of the control group may have become infected. This study did show ten-
dency to lower CD4+ T cell depletion with the A3B deletion during 88 day follow-up [57]. The
role of A3B and the A3B deletion in HIV disease warrants further clarification as their role in
multiple virus, pathogens and cancers increasingly has been recognized [54,58–61].
In this study, we identified a common haplotype tagged by A3F 231V variant as a novel
AIDS-modifying genetic factor in European Americans, which shows a similar trend in African
Americans with HIV infection. A3GH186R is only found in individuals with African ancestry
and is almost absent in European population [30], while the A3B gene deletion is more com-
mon in individuals from Asia and is less frequent in Europeans, and is nearly absent in popula-
tions with West African ancestry. The differences in APOBEC3 variant frequencies and
haplotype structure among continental populations might have arisen from population-spe-
cific demographic events and or from viral selective pressure acting on the APOBEC3 genes.
This study adds new evidence that A3F plays an important role in restricting pathogenesis of
HIV-1 in its natural host. These data support the development of therapeutics targeting the
Vif-A3F axis, along with current efforts on A3G-Vif.
Materials and Methods
Study participants
We used clinically well-characterized subjects from 6 pretreatment HIV/AIDS cohorts. Study
participants (N = 4203) were enrolled in USA-based, prospective natural history HIV/AIDS
cohorts: Multicenter AIDS Cohort Study (MACS) [62], the San Francisco City Clinic Cohort
Study (SFCCC) [63], AIDS Link to the Intravenous Experience (ALIVE) [64], Hemophilia
Growth and Development Study (HGDS) [65], the Multicenter Hemophilia Cohort Study
(MHCS) [66] and DC gay (DCG) [67]. These cohorts were initiated during 1980’s and partici-
pants were followed up semi-annually with blood draws for viral load and CD4+ T cell mea-
surements and physical examinations at each visit. These treatment naïve cohorts have been
used to identify multiple HIV-1/AIDS modifying genetic factors [30,68].
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The study group includes 707 European American HIV-1 incident seroconverters, 281 Afri-
can American incident seroconverters, 1135 HIV-uninfected at-risk individuals and 2076 HIV
seroprevalent individuals who were HIV infected at study entry. The censoring date was the
earliest of the date of the last recorded visit, or July 31, 1997 for the ALIVE cohort, or Decem-
ber 31, 1995 for all other cohorts, to avoid the confounding effect of highly active anti-retrovi-
ral therapy (HAART). A later censoring date was used for ALIVE cohort because few ALIVE
participants received HAART prior to July 31, 1997 [69]. PCP prophylaxis status was only
available for a subset of the MACS cohort; the first self-reported drugs used included Trimeth-
oprim/sulfamethoxazole, aerosolized Pentamidine and Dapsone; the combination or switch-
over of these drugs were used over the clinical course.
Ethics statement
Ethical approval for the study was obtained from the National Institute of Health Office of
Human Subjects Research Protections with OHSRP #3314. Ethical approval was obtained from
institutional review boards for each of the respective contributing centers in the International
Collaboration for the Genomics of HIV. Written informed consent was obtained from all
study participants.
Selection of A3F genetic variants
We selected six SNPs that were codon-changing, in a predicted splicing or regulatory site
(based on SNPinfo web server [http://snpinfo.niehs.nih.gov]), considering SNP spacing and
gene coverage. Several other nonsynonymous variants in A3F are reported in the 1000 genome
project but were not genotyped here either because they were rare or tagged by other SNPs:
rs2020390 (p. A108S) is in near-absolute LD (r2 = 0.94) with rs2076101 (p.I231V) in Europe-
ans. rs34182094 (p. A178T), rs12157816 (p. Y307C), rs13056825 (p.N346S) were absent or
infrequent in Utah Europeans (CEU) and Yoruba Africans (YRI).
Genotyping of A3F genetic variants
SNPs were genotyped using the TaqMan allele discrimination assays on an ABI 7900HT
sequencer detector system (Applied Biosystems), according to the manufacturer’s protocol.
For quality control, water controls were included on each plate and 10% of samples were dupli-
cated. No water contamination or genotype mismatches between duplicates was observed. SNP
rs2076101 was also genotyped by a second in-house designed TaqMan assay (sequences avail-
able upon request); the resulted genotypes were identical by two assays.
Electrophoretic mobility shift assays (EMSA)
EMSA was performed in nuclear extracts from HeLa cell stimulated with PMA using oligonu-
cleotides carrying A3F rs5750728 T/C with an Infrared EMSA Kit (LI-COR), as previously
described [70]. The double-stranded oligonucleotides used were (SNP allele underlined): 5’-CC
CTTTGGCCAGTGCGTCCCACCACAT-3’ and 5’-CCCTTTGGCCAGTGCGCCCCACCAC
AT-3’.
Cell culture, transfection and immunoblot analysis
HEK293T (ATCC, catalog no. CRL-11268) cells were maintained in Dulbecco's modified
Eagle's medium (DMEM, Invitrogen) with 10% fetal bovine serum and penicillin/streptomycin
(D-10 medium) and passaged upon confluence. DNA transfection in HEK293T cells was car-
ried out using Lipofectamine 2000 (Invitrogen) as recommended by the manufacturer. For
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degradation assays, HEK293T cells in 12-well plates were transfected with 1 μg of Vif or 1 μg of
empty vector and 0.3 μg of A3F expression vector at a 3:1 ratio. HEK293T cells were collected
at 48 h after transfection. Cell lysates were lysed in 1x loading buffer (0.08 M Tris, pH 6.8, with
2.0% SDS, 10% glycerol, 0.1 M dithiothreitol and 0.2% bromophenol blue) and boiled for 5
min before separating the proteins by SDS-PAGE. Membranes were probed with various pri-
mary antibodies against proteins of interest. Secondary antibodies were alkaline phosphatase-
conjugated anti-sheep, anti-rabbit or anti-mouse (Jackson Immunoresearch) antibodies, and
staining was carried out with 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tet-
razolium (NBT) solutions prepared from chemicals obtained from Sigma.
Detection of HIV-1 hypermutation
HIV-1 sequences covering the pol gene alone (in half of the patients) or the pol gene with addi-
tional other genes were obtained by the Sanger sequencing from plasma of patients in the Swiss
HIV Cohort Study. A3F specific hypermutation was quantified as in the Los Alamos Hyper-
mut2 tool [38]. Consensus nucleotide sequences of the samples and of the hxb2 reference
sequence were translated to amino acid sequence from which a multiple alignment was created
with muscle [71]. Using the amino acid sequence alignment we derived a codon-aware nucleo-
tide alignment, which was used to count the number of possible hypermutation sites. We
counted the number of trinucleotides matching the “GA[A or T or G]” pattern in the reference
sequence as the number of potential A3F hypermutation sites. The number of actual A3F
induced mutations in each sample was determined as a subset of potential A3F hypermutation
sites where the first nucleotide was an A. It should be noted that GA! AA editing can be
mediated by A3D/F/H [39,41]. To quantify the background mutation level we used the follow-
ing regular expression, which is the same as in the Hypermut2 tool: “G(([CT][ACGT])|([AG]
C))”. The level of hypermutation of a patient sample was determined as an odds ratio: (number
of A3F induced mutations/number of potential A3F specific sites) / (number of background
mutations / number of potential background sites). Statistical tests were carried out on the log-
arithm of the latter quantity using linear regression. The regression included host PCA axes as
covariates, the allele dosage of rs2076101, and an indicator variable indicating the SNP geno-
typing platform.
Statistical analysis
We performed analyses using SAS version 9.12 (SAS Institute, Cary, NC).
We assessed the influences of the A3F variants on disease progression to AIDS outcomes by
the Cox proportional hazards model (Cox model) and Kaplan-Meier survival curve analyses.
We only included seroconverters with known infection dates (midpoint estimation between
last seronegative and first seropositive HIV test) in our analysis. The endpoint was clinical
AIDS diagnosis using the Centers for Disease Control and Prevention (CDC) 1987 definition
of AIDS [34], i.e. HIV-1 infection plus AIDS-defining illness or AIDS-related death. The
median time from seroconversion to AIDS was 10 years in European American seroconverters.
As the Kaplan-Meier survival analysis indicated that the haplotype tagged by rs2076101 best
fitted a dominant genetic model, we compared the heterozygous (231I/V) and homozygous
genotype (231V/V) state to the reference group of homozygotes (231I/I) in a Cox proportional
hazards model. European American and African American groups were analyzed separately
because the allele frequencies were different between the two groups. We included known
genetic factors modifying AIDS progression as covariates in the adjusted Cox model analysis:
CCR5 Δ32, CCR5-59029 (CCR5-2459, rs1799987),HLA-B27,HLA-B57, HLA-B35Px group
(including HLA-B3502, B3503, B3504, and B5301),HLA-C [32] and HLA Class I
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homozygosity for European American (reviewed in [72];HLA-B57 andHLA Class I homozy-
gosity for African American. We stratified the analyses by sex and by age at seroconversion:
0–20,>20–40, and> 40 years. P values for Cox model analysis were from the Wald test.
Although our previous GWAS for association with HIV phenotypes in EA indicated minimal
population substructure (genomic inflation factor λ = 1.01), we conservatively include the first
two eigenvalues from a PCA analysis (EigenSoft) to correct for population stratification [73].
HIV-1 viral load set-point was defined as the mean log10-transfromed copies of HIV-1 RNA
in plasma measured between months 6–33 after seroconversion (2–5 measurements). Viral load
measurements exceeding three-fold (0.5 log10) from the average of all remaining points were
excluded, as previously suggested [35]. We used the t test for analysis of differences between viral
load means of the group carrying 0 or 1 231V allele versus the 231I homozygote group.
The International Collaboration for the Genomics of HIV (ICGH) combined the GWAS
data from 25 cohorts from Europe and North America, including cohorts used in this study
[36]. The genotypes of the A3F SNPs from ICGH were obtained from the previous GWAS data
[36]. The impact of the A3F SNPs on HIV-1 viral load in ICGH was assessed using a fixed-
effect inverse-variance weighted meta-analysis as previously described [36]. A summary of the
selected study groups and cohorts used in the meta-analysis is presented in S3 Table. Viral
load data from a total of 10395 (7266 European Americans, 3129 African Americans) HIV-1
seropositives was used in the meta-analysis.
The impact of A3F variants on HIV-1 infection susceptibility was assessed by comparing
allelic frequencies between the HIV-1 infected group comprising seroconverter and seropreva-
lent persons and the HIV-1 uninfected group composed of persons at risk for HIV. Odds ratios
(OR) and P values were obtained by using a conditional logistic regression test. All P values
were 2-tailed.
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